BioNTech SE’s Post

Cancer poses significant challenges despite advancements in oncology medications. Though the immuno-oncology breakthroughs of the past showed promise in leveraging the immune system against cancer, subsequent developments have fallen short of expectations. Achieving meaningful progress in this field requires certain key factors for success in any biopharma company, particularly those tackling oncology. #CancerResearch #Immunotherapy #Biopharma #Oncology Delivering The Next Evolution In Immuno-Oncology  https://lnkd.in/eU83ie2b By Caroline J Loew, PhD, CEO of Mural Oncology

Findings presented in Chicago at the annual meeting of the American Society of Clinical Oncology (ASCO) significantly broadened the range of breast cancer patients that could benefit from Enhertu, an antibody-drug conjugate designed to deliver toxic chemotherapy directly to tumours. The data showed an “unprecedented” improvement in progression-free survival, supporting the thesis that antibody-drug conjugates can deliver their payloads more specifically to cancer cells. AstraZeneca and Daiichi Sankyo Canada’s Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy – even if they had very low levels of the mutant protein targeted by the drug, according to trial results. Read more on this at: https://lnkd.in/dt7j7bhf Kim MacDonald #breastcancercanada #breastcancerresearch #breastcancerprogress #enhertu #ASCO24 #BCCatASCO24

Annual Immuno-Oncology Summit 2024 https://lnkd.in/eTvH6Q_t #Biomarkers, #Cancer & #Oncology, #Cancer #immunotherapy, #CAR #Therapy, #Cell #Therapy, #Immuno-oncology, #IO #Targeting & #Discovery, #IO #Therapy, #Medical & #Pharma, #networking, #Oncology, #pipeline, #Preclinical #Research, #research

Can precision oncology benefit patients with cancers of unknown primary 📝? The evidence is conflicting regarding the simplistic implementation of precision oncology 🤔, maybe precision oncology v2.0 can get the job done 🚀. This opinion paper reflects on it 👉: https://lnkd.in/e3u2jQpw #precisionmedicine #precisiononcology

Join the FDA Oncology Center of Excellence for a Conversation on Cancer on Feb. 1 in recognition of World Cancer Day. The conversation will focus on the introduction of certain innovative therapeutic classes in the past two decades that have revolutionized the care for patients with chronic myeloid leukemia, multiple myeloma, and melanoma. The discussion will provide an overview of regulatory programs that expedite access to patients, including FDA’s Breakthrough Therapy designation and Accelerated Approval; and the European Medicines Agency’s Prime and Conditional Approval. The panel of patients, investigators and regulators aims to highlight successes from development to approval. This is the second collaboration between OCE and the EMA in this public panel discussion series. Register here: https://lnkd.in/eNM-Gjns #OCEProjectCommunity #cancer #drugdevelopment #FDA #EMA

Advance your Non-Small Cell Lung Cancer (NSCLC) therapeutics with our premier NSCLC In Vivo Screen! Enroll Today: https://hubs.li/Q02FB3BV0 🗓️ Enroll by August 30th to access a comprehensive bank of 60 NSCLC PDX models, including crucial EGFR and KRAS mutant models. Each model is meticulously curated to preserve essential clinical and molecular characteristics for superior in vivo evaluation. Many models are pretreated with the latest targeted therapies, such as checkpoint inhibitors and EGFR-targeted treatments, closely mirroring clinically relevant patient responses. 💡Don't miss this cost-saving opportunity to advance your Non-Small Cell Lung Cancer therapeutics! #NSCLC #CancerResearch #DrugDevelopment #Biobank #PDXModels #CancerTherapeutics #EGFR #KRAS #NonSmallCellLungCancer #oncology #drugscreening #cancertherapy

CTI is excited to attend the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago, IL! Patients remain at the center of cancer therapeutic development, with a focus on reducing outcome disparities, increasing diversity, and expanding patient access to clinical trials. Aligned with CTI’s patient-centric mission, here are some highlights our team is eager to explore at #ASCO24: - Further developments and refinements of ADCs, breaking new ground in solid tumors. - Advancements in cell therapy, TILs, and other innovative therapeutics. - New strategies for treating aggressive and uncommon cancers. - Progress in molecular precision medicine and its implications for cancer diagnosis and prognosis. We look forward to seeing you in Chicago! Connect with our Oncology Experts at https://bit.ly/3UOsBtA and let’s #MoveMedicineForward together in the fight against cancer. #ASCO24 #MovingMedicineForward #ClinicalResearch #ThinkGlobalActLocal #AdvancingHealthcareSolutions #CRO #Oncology

📢 #Erythropoiesis stimulating agents administration was #safe and had no detrimental effect on #survival outcomes in patients receiving adjuvant anti-HER2 treatment for #HER2+ early #breastcancer 📉 Sub-analysis of the #ALTTO trial (NCT00490139) 🗞 The largest retrospective analysis of this topic in #HER2+ early #bcsm is out @ Breast Cancer Research and Treatment 📍 Read more 👉 https://rdcu.be/dqDhS #bcsm #supportivecare #clinicaltrials Institut Jules Bordet, BIG against breast cancer, Frontier Science Foundation-Hellas, National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology, Novartis, GSK

The countdown for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is on and we're excited to meet you in Chicago. Schedule a meeting with our team to discover how our AI-driven spatial biomarkers are advancing next-gen cancer treatments, like bi-specifics, ADCs, and immunotherapies.—because next-gen oncology treatments need next-gen biomarkers! https://bit.ly/3UFaMwY #ASCO24, #biomarkers #spatialbiomarkers #CDx #SpatialBiology #PrecisionOncology #PrecisionMedicine #DigitalPathology #ClinicalTrials #Oncology